The Presence of Anti-TPO Antibodies Increase the Likelihood of Post-I131 Hypothyroidism
Horm Metab Res DOI: 10.1055/a-2205-2052The use of radioactive iodine in the treatment of hyperthyroidism is common
practice. However, a standardized treatment protocol with regard to radioactive
iodine treatment (RAI) remains subject to discussion. We retrospectively
analyzed 100 patient records. Patient diagnosis, age, gender, body mass index
(BMI), dose of radioactive iodine, thyroid size, the 24 h radioiodine
uptake (24 h RAIU) and protein bound iodine (PBI) were deducted, as well
as the use of antithyroid drugs prior to RAI. Biochemical parameters were
obtained, such as TSH, fT4, fT3, Anti-TPO, Anti-TG antibodies and thyroid
stimulating antibodies. After 5 years of follow-up, 46% of the patients
proved to be hypothyroid, whereas 8% of the patients were not cured
after one dose of RAI. One year after RAI, a larger proportion of patients with
a toxic nodule developed hypothyroidism compared to patients with a multinodular
goiter (MNG) (44.2% vs. 21.2%). Radioactive iodine dose, PBI,
RAIU, BMI, size of the thyroid gland, diagnosis, age and TPO-antibodies showed
statistically significant differences in the development of hypothyroidism.
Furthermore, thiamazole pretherapy was shown to be a predictor of
hypothyroidism, as well as a high PBI value, exhibiting a positive predictive
value of 85.2% when the PBI...
Source: Hormone and Metabolic Research - Category: Endocrinology Authors: Quataert, Felix Bravenboer, Bert Keyaerts, Marleen Andreescu, Corina Emilia Tags: Original Article: Endocrine Care Source Type: research
More News: Endocrinology | Hormones | Hyperthyroidism | Hypothyroidism | Iodine | Statistics | Thyroid | Toxicology